CLEAR Outcomes – Bempedoic Acid reduces Cardiovascular Events among Statin-Intolerant Patients
Key Points Bempedoic acid, an ATP citrate lyase inhibitor, has been shown to reduce LDL cholesterol concentrations by 17% to 28% in clinical trials. However, data... Read more.
BrigHTN: Baxdrostat, an aldosterone synthase inhibitor, showed dose-related reductions in blood pressure and safely and effectively lowers blood pressure in patients with resistant hypertension
Key Points In a Phase 2 randomized trial, baxdrostat, a highly potent and selective aldosterone synthase inhibitor, had dose-related reductions in blood pressurein... Read more.
FRESH –First-in-Class Aminopeptidase-A Inhibitor Firibastat Fails in Resistant Hypertension
Key Points Hypertension remains a major public health threat contributing significantly to rates of ischemic heart disease and strokes worldwide despite a wide array... Read more.
PRECISION –Dual Endothelin Receptor Antagonist Aprocitentan Superior to Placebo in Resistant Hypertension
Key Points Despite the many drug classes available to treat hypertension, the prevalence of resistant hypertension (hypertension requiring at least 3 blood pressure... Read more.
RAPID – Self-Administered Etripamil Improves PSVT Conversion to Sinus Rhythm
Key Points -The RAPID study achieved its primary efficacy endpoint of terminating PSVT with self-administered Etripamil using a symptom-based optimal repeat dosing.... Read more.
NOVA – No significant difference in rate of post-op AF with botulinum toxin vs placebo
Key Points: -In a Phase II, dose-ranging trial of epicardial fat pad injection of botulinum toxin type A (AGN-151607) there was no significant differences in the... Read more.
RIVARAD: Post-Procedural Rivaroxaban Use After Radial Access for Coronary Procedures Reduces Radial Artery Occlusion at 30 Days
Key Points: Radial artery occlusion (RAO) is the most common complication after radial access for coronary procedures; while routine intra-procedural heparin administration... Read more.
EPIC-STEMI: Early Routine PCSK-9 Use Added to High Intensity Statin Reduces LDL after Primary PCI for STEMI
Key Points: Early high-intensity statin therapy is standard of practice in acute STEMI patients, but this is often insufficient to achieve LDL targets. PCSK-9 therapy... Read more.
Extended outcomes of BEST: No difference in MACE between PCI and CABG in MVD at 12 years, but higher repeat revascularization and spontaneous MI in PCI arm
Key Points: Previous studies have demonstrated the superiority of CABG over PCI in the treatment of multivessel disease; however, most studies were performed without... Read more.
FLASH: The FlowTriever system has an excellent safety profile in the treatment of pulmonary embolism
Key Points: Mortality for acute PE remains high. While percutaneous mechanical thrombectomy has been used in patients with hemodynamic instability, safety and effectiveness... Read more.
